Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.37 +3.10%

+$0.04 today

Market cap
$104.71M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.25M

Average 0.51M

CBUS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cibus, Inc.NASDAQ: CBUS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$10.92M, compared with -$39.38M a year earlier. Trailing-twelve-month EBITDA was -$62.31M.

Context

  • EBITDA amounted to 2494.3% of revenue in FY2025, down 3175.2 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$7.55M (+91.7%) for the fiscal year ending Dec 2026, a step up from the +62.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.92M+48.6% QoQ
Last fiscal yearDec 2025
-$90.77M+62.4% YoY
LTMMar 2026
-$62.31M+76.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+72.3%+75.6%+3.3 pp
1 year+62.4%+91.7%+29.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(90.77M) USD
Year-over-year change
+62.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CBUS compares with its peers on the latest reported figures

  • CBUS's LTM Mar 2026 EBITDA of -$62.31M is the 7th highest of the 10 companies compared; the peer median is -$52.24M.
  • Its year-over-year change of +76.4% is the 2nd highest of 10, against a peer median of -1.2%.
  • EBITDA amounts to 1453.8% of revenue for CBUS, versus a peer median of 1327.8%.
CBUS Competitors Peer median
EBITDA for CBUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$47.3M +203.4%—18.5%
MNOVMediciNova, Inc.LTM Mar 2026-$11.72M -5.2%—1963.7%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.25M -164.0%——
BMEABiomea Fusion, Inc.LTM Mar 2026-$46.12M +63.6%——
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$52.24M -1.2%—1327.8%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026-$58.88M -297.6%——
CBUSCibus, Inc.LTM Mar 2026-$62.31M +76.4%—1453.8%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$78.19M +0.2%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$82.08M +0.7%——
IMUXImmunic, Inc.LTM Mar 2026-$104.13M -8.2%——
Peer median (excluding CBUS) -$52.24M-1.2%—1327.8%

Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.99M157K1.82M4.26M3.64M
Cost of Revenue28.56M1.53M395K05.92M
Gross Profit(2.57M)(1.38M)1.42M4.26M(2.28M)
Gross Margin-9.9%-877.1%78.3%100.0%-62.8%
Research & Development11.34M11.55M42.37M50.43M44.2M
Selling, General & Admin15.38M9.44M28.91M30.8M26.91M
Operating Expenses26.76M20.99M320.31M262.66M65.18M
Depreciation & Amortization2.34M1.53M4.69M6.86M5.92M
EBITDA(25.43M)(15.21M)(314.59M)(241.64M)(90.77M)
EBITDA Margin-97.9%-9687.9%-17313.4%-5669.5%-2494.3%
Operating Income(29.33M)(22.37M)(318.88M)(258.4M)(67.46M)
Operating Margin-112.9%-14248.4%-17550.0%-6062.8%-1853.9%
Interest Income17K60K527K631K438K
Interest Expense1.43M87K18.89M34.19M35.48M
Other Income / Expenses133K5.48M(18.76M)(24.29M)(64.71M)
Income Before Tax(29.2M)(16.89M)(337.64M)(282.68M)(132.17M)
Pre-Tax Margin-112.4%-10758.6%-18582.4%-6632.7%-3632.1%
Income Tax Expense00(4K)29K29K
Net Income(29.2M)(16.89M)(267.63M)(251.39M)(127.09M)
Net Margin-112.4%-10758.6%-14729.1%-5898.4%-3492.3%
EPS (Basic)(0.05)(0.03)(25.95)(10.83)(2.78)
EPS (Diluted)(0.05)(0.03)(25.95)(10.83)(2.78)
Weighted Avg Shares578.47M578.47M10.31M23.22M457.57M
Weighted Avg Shares (Diluted)578.47M578.47M10.31M23.22M457.57M

Cibus, Inc.

NASDAQ:CBUS

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.